Sofwave Medical Reports Record Second Quarter and First Half 2025 Financial Results and Business Highlights

Core Insights - Sofwave Medical Ltd reported record quarterly revenue of $21 million in Q2 2025, reflecting a 43% year-over-year growth, and expects to achieve operating break-even for the full year [3][4][5] - The company has a strong recurring revenue stream, with $9.2 million in Q2, representing a 53% year-over-year increase, and over 40% of total revenue coming from recurring sources [4][5][9] - Sofwave's innovative technology and FDA clearances are driving rapid adoption in the aesthetic medical device market, with over 600,000 treatments conducted since launch [3][8][9] Financial Highlights - Q2 2025 revenue reached $21 million, a 43% increase from $14.6 million in Q2 2024; gross profit was $15.9 million, up 42% year-over-year [4][5][7] - First half revenue totaled $37.7 million, a 35% increase year-over-year, with gross profit of $28.6 million, reflecting a 36% growth [5][7] - The company generated $3.6 million in cash during Q2 2025, with cash and cash equivalents amounting to $24 million as of June 30, 2025 [4][5] Operational Highlights - Sofwave's technology, SUPERB™, is FDA-cleared for various aesthetic treatments, including wrinkle reduction and muscle toning, enhancing its market position [8][9] - The company has seen significant growth in brand awareness, surpassing 1 million social media followers, which supports its market presence [3][4] - Sofwave's operational discipline and strong balance sheet are key factors in its ongoing growth strategy [3][9]